Work

Antiarrhythmics and double-sequential external defibrillation for management of incessant ventricular fibrillation in a left ventricular assist device

Year: 2025

Type: article

Abstract: About 6.7 million Americans over 20 years of age have heart failure, with a prevalence that is unfortunately projected to increase to affect more than 8 million people older than 18 years of age by 2030.1 Therapies available for patients with advanced heart failure have seen tremendous advances in the last three decades. Since the initial US Food and Drug Administration approval of a durable left ventricular assist device (LVAD) in 1994,2 the number of devices implanted for mechanical circulatory support in the United States, both as bridge-to-transplant and as destination therapy, continues to rise.

Source: HeartRhythm Case Reports

DOI: 10.1016/j.hrcr.2025.02.016

Authors: Ana Florencia Becerra, Alex M. Parker, Mohammad A. Al-Ani, Juan R. Vilaro, Juan M. Aranda, Mustafa M. Ahmed

Institutions: University of Florida Health, University of Florida

Language: English

Topic: Mechanical Circulatory Support Devices

Subfield: Biomedical Engineering

Field: Engineering

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,100